We have placed cookies on your computer to help make this website better. We use a PIWIK Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by PIWIK (e.g. deny use/opt-out).

Statements | Media | Grünenthal Group

The Grünenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation. We are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients.

... About us

We are an independent, family-owned company with headquarters in Aachen, Germany. We are present in 32 countries with affiliates in Europe, Latin America and the USA. Our products are sold in more than 155 countries and we employ around 5,200 employees worldwide.

... Company Overview

Although firmly rooted in Germany, today we are very much a growing global Business.

... History

A mix of strong entrepreneurial spirit, close collaboration and outstanding performance define our approach to leadership alongside a commitment to diversity and inclusivity.

... Leadership

The Supervisory Board advises and controls the Corporate Executive Board and is elected by the shareholders’ summit.

... Supervisory Board

Beyond our overarching purpose – to improve the health of people around the globe – we want to create shared value through sustainability for our company and society as a whole.

... Responsibility

Although firmly rooted in Germany, today we’re very much a growing global business, represented in 30 countries and maintaining production sites in six.

... Global Capabilities

Patients’ needs are at the heart of everything we do; using our passion for science, we develop long-lasting solutions that directly address these needs.

... Products

We are dedicated to creating a better future for our patients, so getting involved with diverse initiatives that support this goal is vital.

... Initiatives

... Our positions

Innovation is at the heart of everything that we do. It’s the driving force behind new ideas and future therapies.

... Research & Development

For us, innovation goes beyond drug development. Our innovation is built on expert knowledge of disease-pathophysiology’s, understanding of the patient, the use of big data and state-of-the-art technologies such as devices that result in innovative solutions for the patients need.

... Strategy

Our R&D pipeline is a source of great excitement – we currently have several new drug candidates and technologies in different phases of development.

... Pipeline

Our key innovation areas are pain and devices and technologies.

... Focus areas

As a research-based pharmaceutical company, Grünenthal recognizes the importance of publicly registering clinical trials and making information including results available.

... Clinical trials

Collaboration with the scientific community is central to our R&D strategy. Let’s work together – collaborate with us!

... Collaborate with us

Ambition is welcome at Grünenthal. Whether you’re a world-class scientist or a talented graduate, together we drive cutting-edge research projects and develop products of the future. Grünenthal offers a culture of opportunity. Join us!

... Jobs and career

From research scientists and high achieving graduates to experts in marketing and production, our open and inclusive culture helps everyone thrive.

... Meet our people

A distinct culture is central to the wellbeing of any organisation. We are Grünenthal has been vital in engaging new employees with our business and guiding our daily work.

... We are Grünenthal

Explore our media section and access a range of materials relating to our company, people, medicines and medical devices.

... Media

Grünenthal is a global leader in pain management and related diseases. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on moving towards our vision of a world free of pain. Explore our recent stories to see what drives us.

... Our Stories

In this section you will find both current and archived press releases published from 2013 onwards by Grünenthal GmbH, Germany.

... Press releases

... Statements

Journalists are invited to use our corporate publications for their reporting. The list contains business related publication like the company presentation or the code of conduct. .

... Corporate publications

Journalists are invited to use images from our library to illustrate their reporting. The library contains company and R&D related pictures.

... Image resources

The library contains a set of company footage. Journalists are invited to use the video material to illustrate their reporting.

... Video resources

Media Statements

2019

Media Statement Grünenthal

7/1/2019

Grünenthal to discontinue Phase III clinical trials of Neridronate in Complex Regional Pain Syndrome (CRPS)

Grünenthal decided to discontinue its two ongoing Phase III clinical trials of Neridronate (KF7013-02 and KF7013-04) in patients with Complex Regional Pain Syndrome (CRPS). The clinical development program had foreseen to randomize 360 people with CRPS in these trials.

... more

Štěpán Kráčala

Head Global Communications

Grünenthal GmbH

52099

Germany

Phone +49 241 569-1335

E-Mail Stepan.Kracala@grunenthal.com